BUFFALO GROVE, Ill.--(BUSINESS WIRE)--Akorn-Strides, LLC today announced the first commercial product launch for the Joint Venture, Rifampin for Injection USP, 600 mg/vial. Rifampin is used in the treatment of all forms of tuberculosis in conjunction with Isoniazid and Ethambutol.
